Similar articles

• Proceedings: A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine.

  Angelo M, Dring LG, Lancaster R, Latham A, Smith RL. Angelo M, et al. Br J Pharmacol. 1975 Oct;55(2):264P. Br J Pharmacol. 1975. PMID: 1201404 Free PMC article. No abstract available.
• [On the hypotensive effect of debrisoquin sulfate (Declinax)].

  Honorato F, Ortolá RP. Honorato F, et al. Rev Med Univ Navarra. 1973 Dec;17(4):339-44. Rev Med Univ Navarra. 1973. PMID: 4807215 Spanish. No abstract available.
• [Treatment of hypertension with the preparation Tendor].

  Stanchev A, Shishmanova Iu, Sheĭtanov I, Georgiev I. Stanchev A, et al. Vutr Boles. 1977;16(6):34-8. Vutr Boles. 1977. PMID: 341531 Clinical Trial. Bulgarian.
• Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.

  Leenen FH. Leenen FH. Can J Cardiol. 2004 Aug;20 Suppl B:77B-82B. Can J Cardiol. 2004. PMID: 15309209 Review.
• Combination versus Monotherapy as Initial Treatment in Hypertension.

  Holzgreve H. Holzgreve H. Herz. 2003 Dec;28(8):725-32. doi: 10.1007/s00059-003-2513-9. Herz. 2003. PMID: 14689107 Review.